



May 26, 2015

## **Akebia to Present at the Jefferies 2015 Global Healthcare Conference**

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015, at 2:00 p.m. Eastern Time. The conference is being held at the Grand Hyatt Hotel in New York City.

A live audio webcast of the presentation will be available on the company's website at <http://ir.akebia.com/events.cfm>. An archived presentation will be available for 90 days.

### **About Akebia Therapeutics**

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients and is also being tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20150526005678/en/>

### **Investors:**

Argot Partners

Andrea Rabney, +1-212-600-1902

[Andrea@argotpartners.com](mailto:Andrea@argotpartners.com)

or

### **Media:**

Argot Partners

Eliza Schleifstein, +1-917-763-8106

[Eliza@argotpartners.com](mailto:Eliza@argotpartners.com)

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media